Enoxaparin
- 1 August 1996
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 10 (2) , 179-190
- https://doi.org/10.2165/00019053-199610020-00009
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- EnoxaparinDrugs, 1995
- Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgeryBritish Journal of Surgery, 1994
- Prophylaxis for Venous Thromboembolism in Hip Fracture SurgeryPharmacoEconomics, 1994
- Cost/ Benefit Aspects on ThromboprophylaxisPathophysiology of Haemostasis and Thrombosis, 1993
- Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.BMJ, 1992
- EnoxaparinDrugs, 1992
- Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysisThe Lancet, 1992
- Economic Impact of Total Hip ArthroplastySouthern Medical Journal, 1988
- A Randomized Controlled Trial of a Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip SurgeryNew England Journal of Medicine, 1986
- In Vitro Coagulant and Amidolytic Methods for Evaluating the Activity of Heparin and a Low Molecular Weight Derivative (PK 10169)Seminars in Thrombosis and Hemostasis, 1985